News | July 16, 2010

Study Shows Anatomically Designed Catheters Reduce Lab Time

July 16, 2010 – Use of anatomically designed catheters reduces lab time by more than one-third compared to traditional point-by-point focal ablation procedures for pulmonary vein isolation (PVI), according to data from the FAST-PVI study, supported by Medtronic Inc. The data were released recently at Cardiostim 2010, the 17th World Congress in Cardiac Electrophysiology and Cardiac Techniques.

PVI is the cornerstone catheter procedure to treat paroxysmal atrial fibrillation (PAF). The anatomically shaped Arctic Front Cardiac CryoAblation Catheter and advanced radiofrequency (RF) Pulmonary Vein Ablation Catheter (PVAC) allowed physicians to more efficiently isolate the pulmonary veins than do focal RF catheters. Acute PVI success rate for the anatomical catheters was 99 percent.

The Arctic Front is approved in Europe to treat paroxysmal atrial fibrillation (AF); PVAC is approved in Europe to treat supraventricular tachycardia (SVT). Both catheters are under investigational use in the United States. Arctic Front is under U.S. Food and Drug Administration (FDA) review for paroxysmal AF and PVAC for the treatment of continuous AF.

The retrospective FAST-PVI study compared procedure time using anatomically designed catheter ablation systems with procedure times of point-by-point focal systems. Results from nine German centers and 444 procedures showed that using anatomical catheters for PVI allows for more efficient procedures, reduced cath lab occupancy time and faster physician procedure time. Of the 245 procedures using anatomical Arctic Front and PVAC catheters, overall staff time lowered by 36 percent, fluoroscopy time was reduced by 33 percent and physician procedure time was reduced by 37 percent.

The goal of catheter ablation is to isolate the pulmonary vein to stop the rapid beating of the upper heart chambers by ablating (or blocking) the conduction pathways that trigger atrial fibrillation (AF). Catheter ablation is a minimally invasive procedure that is recommended after commonly prescribed drugs have failed to achieve acceptable results in symptomatic patients. Previously, AF ablation procedures could only be performed with a time-consuming point-by-point focal ablation technique to create individual lesions to block AF conductivity. Now, anatomically shaped catheters can efficiently create lesions with fewer applications because they have been designed specifically for isolating the pulmonary vein.

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init